cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.14229035
title: Supplementary Material for: Analysis of <b><i>Kytococcus sedentarius</i></b> Strain Isolated from a Dehumidifier Operating in a University Lecture Theatre: Systems for Aerobic Respiration, Resisting Osmotic Stress, and Sensing Nitric Oxide

description: A strain of <i>Kytococcus sedentarius</i> was isolated from a dehumidifier operating in a university lecture theatre. Genome analysis and phenotypic characterisation showed that this strain, <i>K. sedentarius</i> MBB13, was a moderately halotolerant aerobe with a branched aerobic electron transport chain and genes that could contribute to erythromycin resistance. The major compatible solute was glycine betaine, with ectoine and proline being deployed at higher osmolarities. Actinobacteria possess multiple WhiB-like (Wbl) regulatory proteins, and <i>K. sedentarius</i> MBB13 has four (WhiB1, WhiB2, WhiB3, and WhiB7). Wbls are iron-sulfur proteins that regulate gene expression through interactions with RNA polymerase sigma factors and/or other regulatory proteins. Bacterial two-hybrid analyses suggested that WhiB1 and WhiB2, but not WhiB3 and WhiB7, interact with the C-terminal domain of the major sigma factor, σ<sup>A</sup>; no interaction was detected between any of the Wbl proteins and the only alternative sigma factors, σ<sup>B</sup>, σ<sup>H</sup>, or σ<sup>J</sup>. The interaction between σ<sup>A</sup> and WhiB1 or WhiB2 was disrupted in a heterologous system under growth conditions that produce nitric oxide and the iron-sulfur clusters of the isolated WhiB1 and WhiB2 proteins reacted with nitric oxide. Thus, <i>K. sedentarius</i> strain exhibits the major phenotypic characteristics of the type strain and a comprehensive examination of the interactions between its four Wbl proteins and four sigma factors suggested that the Wbl proteins all operate through interaction with σ<sup>A</sup>.
DOI: 10.6084/m9.figshare.14229035.v1
title: Supplementary Material for: Analysis of <b><i>Kytococcus sedentarius</i></b> Strain Isolated from a Dehumidifier Operating in a University Lecture Theatre: Systems for Aerobic Respiration, Resisting Osmotic Stress, and Sensing Nitric Oxide

description: A strain of <i>Kytococcus sedentarius</i> was isolated from a dehumidifier operating in a university lecture theatre. Genome analysis and phenotypic characterisation showed that this strain, <i>K. sedentarius</i> MBB13, was a moderately halotolerant aerobe with a branched aerobic electron transport chain and genes that could contribute to erythromycin resistance. The major compatible solute was glycine betaine, with ectoine and proline being deployed at higher osmolarities. Actinobacteria possess multiple WhiB-like (Wbl) regulatory proteins, and <i>K. sedentarius</i> MBB13 has four (WhiB1, WhiB2, WhiB3, and WhiB7). Wbls are iron-sulfur proteins that regulate gene expression through interactions with RNA polymerase sigma factors and/or other regulatory proteins. Bacterial two-hybrid analyses suggested that WhiB1 and WhiB2, but not WhiB3 and WhiB7, interact with the C-terminal domain of the major sigma factor, σ<sup>A</sup>; no interaction was detected between any of the Wbl proteins and the only alternative sigma factors, σ<sup>B</sup>, σ<sup>H</sup>, or σ<sup>J</sup>. The interaction between σ<sup>A</sup> and WhiB1 or WhiB2 was disrupted in a heterologous system under growth conditions that produce nitric oxide and the iron-sulfur clusters of the isolated WhiB1 and WhiB2 proteins reacted with nitric oxide. Thus, <i>K. sedentarius</i> strain exhibits the major phenotypic characteristics of the type strain and a comprehensive examination of the interactions between its four Wbl proteins and four sigma factors suggested that the Wbl proteins all operate through interaction with σ<sup>A</sup>.
DOI: 10.6084/m9.figshare.14215814
title: af.xlsx

description: This is a test file
DOI: 10.6084/m9.figshare.14215814.v3
title: af.xlsx

description: This is a test file
DOI: 10.6084/m9.figshare.14215814.v2
title: af.xlsx

description: This is a test file
DOI: 10.14457/ku.res.2019.201
title: การพัฒนามือถ่างความละเอียดระดับไมครอนที่ขับเคลื่อนโดยเพียโซอิเล็กทริกสำหรับกระบวนการทดสอบหัวอ่านฮาร์ดดิสก์ (เรื่องเต็มการประชุมทางวิชาการของมหาวิทยาลัยเกษตรศาสตร์ ครั้งที่ 57: สาขาวิทยาศาสตร์และพันธุวิศวกรรม, สาขาสถาปัตยกรรมศาสตร์และวิศวกรรมศาสตร์, สาขาอุตสาหกรรมเกษตร, สาขาทรัพยากรธรรมชาติและสิ่งแวดล้อม)
DOI: 10.14457/ku.res.2019.202
title: การแครกกิ้งน้ำมันกลั่นหนักโดยใช้ตัวเร่งปฏิกิริยา TiO2/ZrO2 และ SO42-/TiO2/HZSM-5 (เรื่องเต็มการประชุมทางวิชาการของมหาวิทยาลัยเกษตรศาสตร์ ครั้งที่ 57: สาขาวิทยาศาสตร์และพันธุวิศวกรรม, สาขาสถาปัตยกรรมศาสตร์และวิศวกรรมศาสตร์, สาขาอุตสาหกรรมเกษตร, สาขาทรัพยากรธรรมชาติและสิ่งแวดล้อม)
DOI: 10.14457/ku.res.2019.203
title: การศึกษาการบ่งชี้ลักษณะ Fault ด้วยค่าพารามิเตอร์ที่มีนัยสำคัญ (เรื่องเต็มการประชุมทางวิชาการของมหาวิทยาลัยเกษตรศาสตร์ ครั้งที่ 57: สาขาวิทยาศาสตร์และพันธุวิศวกรรม, สาขาสถาปัตยกรรมศาสตร์และวิศวกรรมศาสตร์, สาขาอุตสาหกรรมเกษตร, สาขาทรัพยากรธรรมชาติและสิ่งแวดล้อม)
DOI: 10.14457/ku.res.2019.204
title: การปรับปรุงคุณภาพน้ำมันชีวมวลจากต้นกระถินยักษ์สายพันธุ์ มก.5/7 ด้วยตัวเร่งปฏิกิริยา Ni3P/HZSM-5 และ Cu-ZnO/CeO2/ZrO2/Al2O3 (เรื่องเต็มการประชุมทางวิชาการของมหาวิทยาลัยเกษตรศาสตร์ ครั้งที่ 57: สาขาวิทยาศาสตร์และพันธุวิศวกรรม, สาขาสถาปัตยกรรมศาสตร์และวิศวกรรมศาสตร์, สาขาอุตสาหกรรมเกษตร, สาขาทรัพยากรธรรมชาติและสิ่งแวดล้อม)
DOI: 10.14457/ku.res.2019.205
title: การวิเคราะห์ฐานรองรับเครื่องประแจกลไฟฟ้า (เรื่องเต็มการประชุมทางวิชาการของมหาวิทยาลัยเกษตรศาสตร์ ครั้งที่ 57: สาขาวิทยาศาสตร์และพันธุวิศวกรรม, สาขาสถาปัตยกรรมศาสตร์และวิศวกรรมศาสตร์, สาขาอุตสาหกรรมเกษตร, สาขาทรัพยากรธรรมชาติและสิ่งแวดล้อม)
DOI: 10.6084/m9.figshare.12493685
title: An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry

description: <b>Background:</b> In 2013, eribulin was reimbursed under a coverage with evidence development (CED) as third or later chemotherapy line for advanced breast cancer (ABC) patients in the Netherlands because of uncertain cost effectiveness. In 2016, the final decision of reimbursing eribulin was taken without considering the evidence collected during CED research. We analysed the cost effectiveness of eribulin versus non-eribulin chemotherapy, using real-world data. <b>Methods:</b> A three health states (progression-free, progressed disease, dead) partitioned survival model was developed. The SOuth East Netherlands Advanced BREast Cancer (SONABRE) registry informed the effectiveness and costs inputs. Health state utility values were obtained from the literature. Incremental cost-effectiveness ratio (ICER) between the eribulin and matched non-eribulin chemotherapy was estimated. Deterministic and probabilistic sensitivity analyses and scenario analyses were performed. The financial risk (i.e., the expected value of perfect information (EVPI) plus the expected monetary loss (eML) associated with reimbursing eribulin) and budget impact associated with reimbursing eribulin were calculated. <b>Results:</b> Eribulin led to higher health benefits (0.07 quality-adjusted life year (QALY)) and costs (€15,782) compared with non-eribulin chemotherapy. This resulted in an ICER of €239,338. At a €80,000 per QALY threshold, the risk of reimbursing eribulin was €10,516 per patient (EVPI €9, eML €10,507). Scaled up to the Dutch population, the estimated annual budget impact was €1.9 million and the annual risk of reimbursing eribulin was €2.9 million. <b>Conclusion:</b> From a Dutch societal perspective, eribulin is not cost effective when considering its list price as third and later chemotherapy line for ABC patients.
DOI: 10.6084/m9.figshare.12493685.v3
title: An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry

description: <b>Background:</b> In 2013, eribulin was reimbursed under a coverage with evidence development (CED) as third or later chemotherapy line for advanced breast cancer (ABC) patients in the Netherlands because of uncertain cost effectiveness. In 2016, the final decision of reimbursing eribulin was taken without considering the evidence collected during CED research. We analysed the cost effectiveness of eribulin versus non-eribulin chemotherapy, using real-world data. <b>Methods:</b> A three health states (progression-free, progressed disease, dead) partitioned survival model was developed. The SOuth East Netherlands Advanced BREast Cancer (SONABRE) registry informed the effectiveness and costs inputs. Health state utility values were obtained from the literature. Incremental cost-effectiveness ratio (ICER) between the eribulin and matched non-eribulin chemotherapy was estimated. Deterministic and probabilistic sensitivity analyses and scenario analyses were performed. The financial risk (i.e., the expected value of perfect information (EVPI) plus the expected monetary loss (eML) associated with reimbursing eribulin) and budget impact associated with reimbursing eribulin were calculated. <b>Results:</b> Eribulin led to higher health benefits (0.07 quality-adjusted life year (QALY)) and costs (€15,782) compared with non-eribulin chemotherapy. This resulted in an ICER of €239,338. At a €80,000 per QALY threshold, the risk of reimbursing eribulin was €10,516 per patient (EVPI €9, eML €10,507). Scaled up to the Dutch population, the estimated annual budget impact was €1.9 million and the annual risk of reimbursing eribulin was €2.9 million. <b>Conclusion:</b> From a Dutch societal perspective, eribulin is not cost effective when considering its list price as third and later chemotherapy line for ABC patients.
DOI: 10.6084/m9.figshare.12378215
title: Desloratadine and loratadine stand out among common H<sub>1</sub>-antihistamines for association with improved breast cancer survival

description: As tumors maintain an inflammatory microenvironment, anti-inflammatory medication can be useful in cancer therapy. We have previously shown an association with improved survival in melanoma for use of the H<sub>1</sub>-antihistamines desloratadine and loratadine, and here we examine use of H<sub>1</sub>-antihistamines and breast cancer mortality. We investigated use of the six major H<sub>1</sub>-antihistamines (cetirizine, clemastine, desloratadine, ebastine, fexofenadine and loratadine) and breast cancer-specific and overall mortality in a nation-wide register-based study of all 61,627 Swedish women diagnosed with breast cancer 2006–2013. Both peri- and post-diagnostic antihistamine use was analyzed using Cox regression models. Analyses were stratified for age and subgroup analyses based on estrogen receptor status and menopausal status were performed. We found a consistently improved survival of desloratadine users (HR = 0.67; 95% CI 0.55–0.81, <i>p</i> p = .012), relative to nonusers, regardless of patient age, menopause, estrogen receptor status or stage of the tumor, or whether breast cancer-specific or overall survival was analyzed. The survival of users of other antihistamines varied relative to non-users. Based on their safety and current use within the patient population, together with our observations, we suggest the initiation of trials of desloratadine and loratadine as treatment of breast cancer as well as studies of the mechanism behind their possible effect. Further studies on any effects of other H<sub>1</sub>-antihistamines may also be merited, as well as of H<sub>1</sub>-antihistamine use and survival in other malignancies.
DOI: 10.6084/m9.figshare.12378215.v1
title: Desloratadine and loratadine stand out among common H<sub>1</sub>-antihistamines for association with improved breast cancer survival

description: As tumors maintain an inflammatory microenvironment, anti-inflammatory medication can be useful in cancer therapy. We have previously shown an association with improved survival in melanoma for use of the H<sub>1</sub>-antihistamines desloratadine and loratadine, and here we examine use of H<sub>1</sub>-antihistamines and breast cancer mortality. We investigated use of the six major H<sub>1</sub>-antihistamines (cetirizine, clemastine, desloratadine, ebastine, fexofenadine and loratadine) and breast cancer-specific and overall mortality in a nation-wide register-based study of all 61,627 Swedish women diagnosed with breast cancer 2006–2013. Both peri- and post-diagnostic antihistamine use was analyzed using Cox regression models. Analyses were stratified for age and subgroup analyses based on estrogen receptor status and menopausal status were performed. We found a consistently improved survival of desloratadine users (HR = 0.67; 95% CI 0.55–0.81, <i>p</i> p = .012), relative to nonusers, regardless of patient age, menopause, estrogen receptor status or stage of the tumor, or whether breast cancer-specific or overall survival was analyzed. The survival of users of other antihistamines varied relative to non-users. Based on their safety and current use within the patient population, together with our observations, we suggest the initiation of trials of desloratadine and loratadine as treatment of breast cancer as well as studies of the mechanism behind their possible effect. Further studies on any effects of other H<sub>1</sub>-antihistamines may also be merited, as well as of H<sub>1</sub>-antihistamine use and survival in other malignancies.
DOI: 10.6084/m9.figshare.12403817
title: Survival after breast cancer in women with type 2 diabetes using antidiabetic medication and statins: a retrospective cohort study

description: <b>Background:</b> We assessed survival of breast cancer in women with type 2 diabetes (T2D) treated with metformin, other types of antidiabetic medication (ADM) and statins. <b>Materials and Methods:</b> The study cohort consisted of women with T2D and diagnosed with breast cancer in Finland in 1998─2011. Mortality rates from breast cancer and other causes were analysed by Cox models, and adjusted hazard ratios (HRs) with 95% confidence intervals (Cls) were estimated in relation to the use of different types of medication. <b>Results:</b> The final cohort consisted of 3,533 women. No clear evidence was found for breast cancer mortality being different in metformin users (HR 0.86, 95% Cl 0.63–1.17), but their other-cause mortality appeared to be lower (HR 0.73, 95% Cl 0.55–0.97) in comparison with women using other types of oral ADM. Other-cause mortality was higher among insulin users (HR 1.45, 95% Cl 1.16–1.80) compared with users of other oral ADMs, other than metformin. Prediagnostic statin use was observed to be associated with decreased mortality from both breast cancer (HR 0.76, 95% Cl 0.63–0.92) and other causes (HR 0.75, 95% Cl 0.64–0.87). <b>Conclusions:</b> We did not find any association between ADM use and disease-specific mortality among women with T2D diagnosed with breast cancer. However, interestingly, prediagnostic statin use was observed to predict reduced mortality from breast cancer and other causes. We hypothesise that treating treatment practices of T2D or hypercholesterolaemia of breast cancer patients might affect overall prognosis of women diagnosed with breast cancer and T2D.
DOI: 10.6084/m9.figshare.12301727
title: Rate of locoregional recurrence among patients with oropharyngeal squamous cell carcinoma with known HPV status: a systematic review

description: <b>Background:</b> We aimed to review systematically the literature on locoregional recurrence rates in patients with HPV-positive and -negative oropharyngeal squamous cell carcinoma (OPSCC). <b>Methods:</b> PubMed and Embase databases were systematically searched using key words such as human papillomavirus, oropharyngeal squamous cell carcinoma with local, regional, and locoregional recurrence. <b>Results:</b> Nine studies (2974 patients with known HPV-status, 59% HPV-positive) were included. Among the HPV-positive and -negative patients, 69% and 58% had lymph node metastasis at diagnosis. At a median time to recurrence ranging from 8.4 to 13.2 months among the included studies, we found that a weighted average of 9% and 26% for HPV-positive and -negative patients experienced locoregional recurrence. Overall, the median follow-up time ranged from 21 to 83 months among the included studies. <b>Conclusion:</b> Recurrence rates for HPV-positive and -negative OPSCC patients were 9% and 26%, respectively, equating to an almost three times higher rate of locoregional recurrence among HPV-negative patients compared to HPV-positive patients.
DOI: 10.6084/m9.figshare.12301727.v1
title: Rate of locoregional recurrence among patients with oropharyngeal squamous cell carcinoma with known HPV status: a systematic review

description: <b>Background:</b> We aimed to review systematically the literature on locoregional recurrence rates in patients with HPV-positive and -negative oropharyngeal squamous cell carcinoma (OPSCC). <b>Methods:</b> PubMed and Embase databases were systematically searched using key words such as human papillomavirus, oropharyngeal squamous cell carcinoma with local, regional, and locoregional recurrence. <b>Results:</b> Nine studies (2974 patients with known HPV-status, 59% HPV-positive) were included. Among the HPV-positive and -negative patients, 69% and 58% had lymph node metastasis at diagnosis. At a median time to recurrence ranging from 8.4 to 13.2 months among the included studies, we found that a weighted average of 9% and 26% for HPV-positive and -negative patients experienced locoregional recurrence. Overall, the median follow-up time ranged from 21 to 83 months among the included studies. <b>Conclusion:</b> Recurrence rates for HPV-positive and -negative OPSCC patients were 9% and 26%, respectively, equating to an almost three times higher rate of locoregional recurrence among HPV-negative patients compared to HPV-positive patients.
DOI: 10.6084/m9.figshare.12493685.v2
title: An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry

description: <b>Background:</b> In 2013, eribulin was reimbursed under a coverage with evidence development (CED) as third or later chemotherapy line for advanced breast cancer (ABC) patients in the Netherlands because of uncertain cost effectiveness. In 2016, the final decision of reimbursing eribulin was taken without considering the evidence collected during CED research. We analysed the cost effectiveness of eribulin versus non-eribulin chemotherapy, using real-world data. <b>Methods:</b> A three health states (progression-free, progressed disease, dead) partitioned survival model was developed. The SOuth East Netherlands Advanced BREast Cancer (SONABRE) registry informed the effectiveness and costs inputs. Health state utility values were obtained from the literature. Incremental cost-effectiveness ratio (ICER) between the eribulin and matched non-eribulin chemotherapy was estimated. Deterministic and probabilistic sensitivity analyses and scenario analyses were performed. The financial risk (i.e., the expected value of perfect information (EVPI) plus the expected monetary loss (eML) associated with reimbursing eribulin) and budget impact associated with reimbursing eribulin were calculated. <b>Results:</b> Eribulin led to higher health benefits (0.07 quality-adjusted life year (QALY)) and costs (€15,321) compared with non-eribulin chemotherapy. This resulted in an ICER of €220,608. At a €80,000 per QALY threshold, the risk of reimbursing eribulin was €9,791 per patient (EVPI €13, eML €9,778). Scaled up to the Dutch population, the estimated annual budget impact was €1.9 million and the annual risk of reimbursing eribulin was €2.7 million. <b>Conclusion:</b> From a Dutch societal perspective, eribulin is not cost effective when considering its list price as third and later chemotherapy line for ABC patients.
DOI: 10.6084/m9.figshare.12403817.v1
title: Survival after breast cancer in women with type 2 diabetes using antidiabetic medication and statins: a retrospective cohort study

description: <b>Background:</b> We assessed survival of breast cancer in women with type 2 diabetes (T2D) treated with metformin, other types of antidiabetic medication (ADM) and statins. <b>Materials and Methods:</b> The study cohort consisted of women with T2D and diagnosed with breast cancer in Finland in 1998─2011. Mortality rates from breast cancer and other causes were analysed by Cox models, and adjusted hazard ratios (HRs) with 95% confidence intervals (Cls) were estimated in relation to the use of different types of medication. <b>Results:</b> The final cohort consisted of 3,533 women. No clear evidence was found for breast cancer mortality being different in metformin users (HR 0.86, 95% Cl 0.63–1.17), but their other-cause mortality appeared to be lower (HR 0.73, 95% Cl 0.55–0.97) in comparison with women using other types of oral ADM. Other-cause mortality was higher among insulin users (HR 1.45, 95% Cl 1.16–1.80) compared with users of other oral ADMs, other than metformin. Prediagnostic statin use was observed to be associated with decreased mortality from both breast cancer (HR 0.76, 95% Cl 0.63–0.92) and other causes (HR 0.75, 95% Cl 0.64–0.87). <b>Conclusions:</b> We did not find any association between ADM use and disease-specific mortality among women with T2D diagnosed with breast cancer. However, interestingly, prediagnostic statin use was observed to predict reduced mortality from breast cancer and other causes. We hypothesise that treating treatment practices of T2D or hypercholesterolaemia of breast cancer patients might affect overall prognosis of women diagnosed with breast cancer and T2D.
DOI: 10.6084/m9.figshare.12850940.v1
title: Association between variations in the number of hospital beds and inpatient chemo/radiotherapy for breast cancer: a study using a large claim database

description: Chemo/radiotherapy for breast cancer patients does not require hospitalisation in most cases. We investigated the relationship between the proportion of hospitalisation for chemo/radiotherapy over total hospitalisation and the number of hospital beds per capita among breast cancer cases. A retrospective observational study. Hospitals in Japan. In total, 561,165 records of hospitalisation of breast cancer cases were extracted from the Japanese Diagnosis Procedure Combination database from April 2012 to March 2016. <b>Intervention(s) and main outcome measure(s):</b> A multivariable beta regression model accounting for the clustering effect within each prefecture was used to examine the relationship between the number of hospital beds per capita in each prefecture and the proportion of hospitalisation for inpatient chemo/radiotherapy treatment or the number of surgical operations for breast cancer patients in each prefecture. The proportion of hospitalisation for inpatient chemo/radiotherapy treatment varied from 2.6% to 61.8% in 2016. The logit proportion of hospitalisation for inpatient chemo/radiotherapy treatment was significantly higher for every additional hospital bed per capita (0.0027, 95% confidence interval (95% CI) 0.0014–0.0040). In contrast, no significant relationship was observed between the number of surgical operations for breast cancer per capita and the number of hospital beds per capita. We found that a higher number of regional hospital beds were associated with a higher proportion of hospitalisation for chemo/radiotherapy treatment, suggesting that inpatient chemo/radiotherapy may be a provider-induced practice.